ScinoPharm Taiwan Ltd (台灣神隆) yesterday said it expects sales to grow steadily this year, but added that it plans to diversify its business from generic active pharmaceutical ingredients (API) to contract manufacturing and research services in a bid to avoid an intense price competition in the generic API market.
The Tainan-based pharmaceutical company reported revenue of NT$3.52 billion (US$114.3 million) for last year, inching up 0.2 percent from a year earlier.
However, thanks to cost controls, net profit rose 4.9 percent annually to NT$443 million, or earnings per share of NT$0.56, the company said.
Revenue from generic API accounted for 65 percent of total revenue, maintaining its top ranking, while combined revenue from contract manufacturing and research services made up 34 percent, company data showed.
ScinoPharm this year expects to gain regulatory approval in the US to supply generic APIs for a treatment for breast cancer and benign prostatic hyperplasia, as well as approvals in China and Japan for two other generic APIs, ScinoPharm marketing and sales vice president Portia Lin (林靜雯) told an investors’ conference in Taipei.
“However, we found that the prices of generic APIs fell significantly due to intense competition, and we could not win over our peers in countries with lower manufacturing costs, such as India and China,” Lin said.
ScinoPharm’s revenue from generic APIs last year fell 5.6 percent annually to NT$75.8 million, but revenue from contract manufacturing and research services jumped 10.4 percent and 64.7 percent annually to NT$17.2 million and NT$22.4 million respectively, company data showed.
Instead of seeking more API clients, the company plans to expand its contract manufacturing and research services this year, in the hope of boosting revenue contribution from the two segments to 40 percent of overall revenue.
This year, the company aims to focus more on the markets in Japan and China, which offer faster growth opportunities, compared with slowing growth in the US and Europe, where opportunities are further constrained by large-scale mergers and acquisitions in the pharmaceuticals sector, ScinoPharm said.
ScinoPharm shares yesterday rose 1.14 percent to NT$26.7 in Taipei. They have advanced 10.56 percent since the beginning of this year, compared with the broader market’s 9.41 percent rise over the same period.
Real estate agent and property developer JSL Construction & Development Co (愛山林) led the average compensation rankings among companies listed on the Taiwan Stock Exchange (TWSE) last year, while contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) finished 14th. JSL Construction paid its employees total average compensation of NT$4.78 million (US$159,701), down 13.5 percent from a year earlier, but still ahead of the most profitable listed tech giants, including TSMC, TWSE data showed. Last year, the average compensation (which includes salary, overtime, bonuses and allowances) paid by TSMC rose 21.6 percent to reach about NT$3.33 million, lifting its ranking by 10 notches
Popular vape brands such as Geek Bar might get more expensive in the US — if you can find them at all. Shipments of vapes from China to the US ground to a near halt last month from a year ago, official data showed, hit by US President Donald Trump’s tariffs and a crackdown on unauthorized e-cigarettes in the world’s biggest market for smoking alternatives. That includes Geek Bar, a brand of flavored vapes that is not authorized to sell in the US, but which had been widely available due to porous import controls. One retailer, who asked not to be named, because
SEASONAL WEAKNESS: The combined revenue of the top 10 foundries fell 5.4%, but rush orders and China’s subsidies partially offset slowing demand Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) further solidified its dominance in the global wafer foundry business in the first quarter of this year, remaining far ahead of its closest rival, Samsung Electronics Co, TrendForce Corp (集邦科技) said yesterday. TSMC posted US$25.52 billion in sales in the January-to-March period, down 5 percent from the previous quarter, but its market share rose from 67.1 percent the previous quarter to 67.6 percent, TrendForce said in a report. While smartphone-related wafer shipments declined in the first quarter due to seasonal factors, solid demand for artificial intelligence (AI) and high-performance computing (HPC) devices and urgent TV-related orders
STILL LOADED: Last year’s richest person, Quanta Computer Inc chairman Barry Lam, dropped to second place despite an 8 percent increase in his wealth to US$12.6 billion Staff writer, with CNA Daniel Tsai (蔡明忠) and Richard Tsai (蔡明興), the brothers who run Fubon Group (富邦集團), topped the Forbes list of Taiwan’s 50 richest people this year, released on Wednesday in New York. The magazine said that a stronger New Taiwan dollar pushed the combined wealth of Taiwan’s 50 richest people up 13 percent, from US$174 billion to US$197 billion, with 36 of the people on the list seeing their wealth increase. That came as Taiwan’s economy grew 4.6 percent last year, its fastest pace in three years, driven by the strong performance of the semiconductor industry, the magazine said. The Tsai
RSS